Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

ACS pharmacology & translational science

Li J, Fukase Y, Shang Y, Zou W, Muñoz-Félix JM, Buitrago L, van Agthoven J, Zhang Y, Hara R, Tanaka Y, Okamoto R, Yasui T, Nakahata T, Imaeda T, Aso K, Zhou Y, Locuson C, Nesic D, Duggan M, Takagi J, Vaughan RD, Walz T, Hodivala-Dilke K, Teitelbaum SL, Arnaout MA, Filizola M, Foley MA, Coller BS.
PMID: 32259072
ACS Pharmacol Transl Sci. 2019 Aug 02;2(6):387-401. doi: 10.1021/acsptsci.9b00041. eCollection 2019 Dec 13.

The integrin αVβ3 receptor has been implicated in several important diseases, but no antagonists are approved for human therapy. One possible limitation of current small-molecule antagonists is their ability to induce a major conformational change in the receptor that...

Cite
Li J, Fukase Y, Shang Y, et al. Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations. ACS Pharmacol Transl Sci. 2019;2(6):387-401doi: 10.1021/acsptsci.9b00041.
Li, J., Fukase, Y., Shang, Y., Zou, W., Muñoz-Félix, J. M., Buitrago, L., van Agthoven, J., Zhang, Y., Hara, R., Tanaka, Y., Okamoto, R., Yasui, T., Nakahata, T., Imaeda, T., Aso, K., Zhou, Y., Locuson, C., Nesic, D., Duggan, M., Takagi, J., Vaughan, R. D., Walz, T., Hodivala-Dilke, K., Teitelbaum, S. L., Arnaout, M. A., Filizola, M., Foley, M. A., & Coller, B. S. (2019). Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations. ACS pharmacology & translational science, 2(6), 387-401. https://doi.org/10.1021/acsptsci.9b00041
Li, Jihong, et al. "Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations." ACS pharmacology & translational science vol. 2,6 (2019): 387-401. doi: https://doi.org/10.1021/acsptsci.9b00041
Li J, Fukase Y, Shang Y, Zou W, Muñoz-Félix JM, Buitrago L, van Agthoven J, Zhang Y, Hara R, Tanaka Y, Okamoto R, Yasui T, Nakahata T, Imaeda T, Aso K, Zhou Y, Locuson C, Nesic D, Duggan M, Takagi J, Vaughan RD, Walz T, Hodivala-Dilke K, Teitelbaum SL, Arnaout MA, Filizola M, Foley MA, Coller BS. Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations. ACS Pharmacol Transl Sci. 2019 Aug 02;2(6):387-401. doi: 10.1021/acsptsci.9b00041. eCollection 2019 Dec 13. PMID: 32259072; PMCID: PMC7088984.
Copy Download .nbib Format: NLM
Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead.

Thrombosis and haemostasis

Fabris E, Korjian S, Coller BS, Ten Berg JM, Granger CB, Gibson CM, van 't Hof AWJ.
PMID: 33677829
Thromb Haemost. 2021 Dec;121(12):1562-1573. doi: 10.1055/a-1414-5009. Epub 2021 Mar 07.

Early recanalization of the infarct-related artery to achieve myocardial reperfusion is the primary therapeutic goal in patients with ST-elevation myocardial infarction (STEMI). To decrease the duration of ischaemia, continuous efforts have been made to improve pre-hospital treatment and to...

Cite
Fabris E, Korjian S, Coller BS, et al. Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thromb Haemost. 2021;121(12):1562-1573doi: 10.1055/a-1414-5009.
Fabris, E., Korjian, S., Coller, B. S., Ten Berg, J. M., Granger, C. B., Gibson, C. M., & van 't Hof, A. W. J. (2021). Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thrombosis and haemostasis, 121(12), 1562-1573. https://doi.org/10.1055/a-1414-5009
Fabris, Enrico, et al. "Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead." Thrombosis and haemostasis vol. 121,12 (2021): 1562-1573. doi: https://doi.org/10.1055/a-1414-5009
Fabris E, Korjian S, Coller BS, Ten Berg JM, Granger CB, Gibson CM, van 't Hof AWJ. Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thromb Haemost. 2021 Dec;121(12):1562-1573. doi: 10.1055/a-1414-5009. Epub 2021 Mar 07. PMID: 33677829; PMCID: PMC8604087.
Copy Download .nbib Format: NLM
Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets.

Journal of clinical and translational science

Vootukuri S, Li J, Nedelman M, Thomas C, Jiang JK, Babayeva M, Coller BS.
PMID: 31544007
J Clin Transl Sci. 2019 Jun;3(2):65-74. doi: 10.1017/cts.2019.382. Epub 2019 Jun 28.

INTRODUCTION: We are developing the novel αIIbβ3 antagonist, RUC-4, for subcutaneously (SC)-administered first-point-of-medical-contact treatment for ST Segment Elevated Myocardial Infarction (STEMI).METHODS: We studied the: 1. pharmacokinetics (PK) of RUC-4 at 1.0, 1.93, and 3.86 mg/kg IV, IM, and SC...

Cite
Vootukuri S, Li J, Nedelman M, et al. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019;3(2):65-74doi: 10.1017/cts.2019.382.
Vootukuri, S., Li, J., Nedelman, M., Thomas, C., Jiang, J. K., Babayeva, M., & Coller, B. S. (2019). Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. Journal of clinical and translational science, 3(2), 65-74. https://doi.org/10.1017/cts.2019.382
Vootukuri, Spandana, et al. "Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets." Journal of clinical and translational science vol. 3,2 (2019): 65-74. doi: https://doi.org/10.1017/cts.2019.382
Vootukuri S, Li J, Nedelman M, Thomas C, Jiang JK, Babayeva M, Coller BS. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019 Jun;3(2):65-74. doi: 10.1017/cts.2019.382. Epub 2019 Jun 28. PMID: 31544007; PMCID: PMC6753935.
Copy Download .nbib Format: NLM
αIIbβ3 binding to a fibrinogen fragment lacking the γ-chain dodecapeptide is activation dependent and EDTA inducible.

Blood advances

Zafar H, Shang Y, Li J, David GA, Fernandez JP, Molina H, Filizola M, Coller BS.
PMID: 29296957
Blood Adv. 2017 Feb 22;1(7):417-428. doi: 10.1182/bloodadvances.2017004689. eCollection 2017 Feb 28.

Platelet integrin receptor αIIbβ3 supports platelet aggregation by binding fibrinogen. The interaction between the fibrinogen C-terminal γ-chain peptide composed of residues γ-404-411 (GAKQAGDV) and the Arg-Gly-Asp (RGD) binding pocket on αIIbβ3 is required for fibrinogen-mediated platelet aggregation, but data...

Cite
Zafar H, Shang Y, Li J, et al. αIIbβ3 binding to a fibrinogen fragment lacking the γ-chain dodecapeptide is activation dependent and EDTA inducible. Blood Adv. 2017;1(7):417-428doi: 10.1182/bloodadvances.2017004689.
Zafar, H., Shang, Y., Li, J., David, G. A., Fernandez, J. P., Molina, H., Filizola, M., & Coller, B. S. (2017). αIIbβ3 binding to a fibrinogen fragment lacking the γ-chain dodecapeptide is activation dependent and EDTA inducible. Blood advances, 1(7), 417-428. https://doi.org/10.1182/bloodadvances.2017004689
Zafar, Hina, et al. "αIIbβ3 binding to a fibrinogen fragment lacking the γ-chain dodecapeptide is activation dependent and EDTA inducible." Blood advances vol. 1,7 (2017): 417-428. doi: https://doi.org/10.1182/bloodadvances.2017004689
Zafar H, Shang Y, Li J, David GA, Fernandez JP, Molina H, Filizola M, Coller BS. αIIbβ3 binding to a fibrinogen fragment lacking the γ-chain dodecapeptide is activation dependent and EDTA inducible. Blood Adv. 2017 Feb 22;1(7):417-428. doi: 10.1182/bloodadvances.2017004689. eCollection 2017 Feb 28. PMID: 29296957; PMCID: PMC5738983.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries